On the other hand, we added the clinicopathological features of ccRCC patients and clarified that based on the retrospective study, IFN-γ response clusters and RBCK1 cannot yet be used as decision aids to spare patients from immunotherapy and/or clinical treatment management. The gene discussed is RBCK1; the disease is nonpapillary renal cell carcinoma.